History
2022: Head of Vyera fined $64.6 million for 55.5 times the price of the drug for toxoplasmosis
In mid-January 2022, a US court suspended Martin Shkreli from pharmaceutical activities for life and ordered him to pay $64.6 million in connection with his decision to set a 55.5-fold price for the drug for toxoplasmosis Daraprim and the struggle to block competitors who produce generics. More details here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |